» Articles » PMID: 15112168

Achievement of Target Blood Pressure Levels in Chronic Kidney Disease: a Salty Question?

Overview
Journal Am J Kidney Dis
Specialty Nephrology
Date 2004 Apr 28
PMID 15112168
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

A large body of evidence supports the validity of lowering blood pressure (BP) to prevent cardiovascular (CV) disease in the general population. This issue becomes even more critical in renal patients because they carry a greater CV risk across the entire spectrum of chronic kidney disease (CKD). In these patients, achievement of lower BP levels also is fundamental to limit the progression of renal damage, especially in the presence of significant proteinuria. Although expert panels have strongly recommended to intensively decrease BP in patients with CKD, management of hypertension in these patients remains inadequate. Armed with the knowledge of the extreme salt-sensitivity of BP in patients with CKD, it is reasonable to hypothesize that more aggressive treatment of volume expansion can be helpful. Nevertheless, although abundant literature has evidenced that dietary sodium restriction decreases BP levels in patients with essential hypertension, no large and prospective study has been conducted to date on this issue in patients with CKD. A potential reason is the low compliance of patients with CKD to dietary prescriptions; however, this problem can be overcome by specific counseling. Alternatively, loop diuretics administered at a high dose should represent the cornerstone of therapy, but, again, well-designed studies verifying the effectiveness of these agents in a large CKD population are still awaited. Nephrologists seem to be reluctant to adequately administer diuretics because of the fear of adverse events. Conversely, the major detrimental effect, that is, excessive hypovolemia, can be prevented if daily body weight loss is limited to 0.3 to 0.5 kg during the initial period of treatment.

Citing Articles

Integrating the new pharmacological standard of care with traditional nutritional interventions in non-dialysis CKD.

De Nicola L, Cupisti A, DAlessandro C, Gesualdo L, Santoro D, Bellizzi V J Nephrol. 2024; 38(1):61-73.

PMID: 39508986 DOI: 10.1007/s40620-024-02135-y.


Blood pressure control in diabetic kidney disease: a post-hoc analysis of the FANTASTIC trial.

Park C, Hong S, Kim S, Shin S, Kim D, Lee J Clin Hypertens. 2024; 30(1):20.

PMID: 39085979 PMC: 11293031. DOI: 10.1186/s40885-024-00280-x.


Chronic Kidney Disease: Underlying Molecular Mechanisms-A Special Issue Overview.

Belo L, Carvalho M Int J Mol Sci. 2023; 24(15).

PMID: 37569736 PMC: 10418376. DOI: 10.3390/ijms241512363.


Therapeutic roles of thiazides and loop diuretics in blood pressure control and renal protection against chronic kidney disease.

Jo W, Koh E, Chung S Clin Hypertens. 2023; 29(1):14.

PMID: 37183259 PMC: 10184374. DOI: 10.1186/s40885-023-00238-5.


Thiazide diuretics are back in CKD: the case of chlorthalidone.

Minutolo R, De Nicola L, Mallamaci F, Zoccali C Clin Kidney J. 2023; 16(1):41-51.

PMID: 36726437 PMC: 9871852. DOI: 10.1093/ckj/sfac198.